UCSF Gets American Heart Association Award as Fit-Friendly Employer
<p>UCSF was recently recognized as a 2011 gold-level recipient of the American Heart Association’s Start! Fit-Friendly Companies Recognition program. </p>
![Placeholder image](/themes/custom/ucsf/images/card/transparent-news-card.png)
University of California San Francisco
Give to UCSF<p>UCSF was recently recognized as a 2011 gold-level recipient of the American Heart Association’s Start! Fit-Friendly Companies Recognition program. </p>
<p>Since reviewing the results of the 2011 employee engagement survey, UCSF has been working to ensure everyone knows exactly what is expected of them and to foster an environment where everyone can thrive.</p>
Mifepristone, a drug approved by the U.S. Food and Drug Administration for terminating early pregnancy, might prove effective in preventing stress-induced relapse in recovering male alcoholics, based on findings in rats reported by researchers at the Ernest Gallo Clinic and Research Center at UCSF.
Scientists at the UCSF-affiliated Gladstone Institutes have identified a protein that kick–starts the response to low levels of oxygen, suggesting new lines of research relevant to a variety of potentially fatal disorders associated with diminished oxygen supply, including cancer, heart disease, stroke and other neurological conditions that affect millions of people worldwide.
<p>UCSF's pioneering program in Development and Stem Cell Biology attracts the nation's best faculty and students who are interested in understanding how embryos develop and how cells make tissues and organs – information needed to design novel therapies to cure diseases and treat injuries.</p>
<p>The University of California has begun work to deploy an integrated payroll and human resource system across all 10 campuses and five medical centers to streamline business operations and save money.</p>
<p>The UCSF “D’Vice Squad,” a group of innovators from across the Bay Area, has drawn from diverse disciplines over the last two years to develop medical devices for children. </p>
An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America.
Scientists at the Gladstone Institutes have discovered how a form of the protein linked to Huntington’s disease influences the timing and severity of its symptoms, offering new avenues for treating not only this disease, but also a variety of similar conditions.
<p>The San Francisco Bay Area Science Festival offers more than 100 mostly free events to put science and technology at everybody's fingertips and to encourage the next generation of scientists and innovators.</p>